Edgewise Therapeutics heads into mid-June with a notable divergence: the Street is turning more bullish at precisely the moment short sellers are adding exposure and options traders are flashing their most defensive reading in months.
The analyst catalyst is the headline this week. RBC Capital raised its price target to $59 from $48 — a 23% lift — while maintaining its Outperform rating, issued today. That move follows Goldman Sachs also raising its target, to $32 from $20, though Goldman stays Neutral. The split tells the story neatly: RBC and Wedbush (which lifted to $52 in early June) see a pipeline re-rating story building around EDG-7500 and the upcoming CIRRUS readout in Q2. Goldman's Neutral at $32, a target now sitting below the $33.95 close, reflects scepticism about the transition following the Sevasemten sale to Servier and the stock's valuation versus cash burn. The consensus is a buy at a mean target of $46.09 — implying around 36% upside — but that average masks a wide range of conviction. HC Wainwright holds at $45, JP Morgan at $45. None has moved to Sell, but Goldman's revised target being essentially at-the-money is a meaningful signal from a bellwether firm.
Short interest is running at 10.4% of free float — a level that deserves attention. It has climbed around 5% over the past week and nearly 10% over the past month, reaching just over 11 million shares. That is a deliberate rebuild, not noise. Days to cover stands at 11.1 per the latest FINRA settlement data. Against that picture, the borrow market tells a less urgent story: availability is exceptionally loose at 1,319%, meaning there are more than thirteen shares available to borrow for every one already out on loan. Cost to borrow ticked up 16% on the week but remains negligible at 0.53%. Bears can add positions cheaply and freely — the squeeze conditions that occasionally amplify moves in high-SI biotech names are simply not present here.
Options positioning has spiked sharply, and that is the most technically striking reading this week. The put/call ratio jumped to 0.39 on Tuesday, nearly four standard deviations above its 20-day mean of 0.32 — the z-score of 3.95 is the kind of reading that marks an unusual single-session demand for downside protection. That said, 0.39 remains in absolute terms a relatively modest ratio; the 52-week high is 0.92. The spike appears to coincide with the 3.6% single-day drop on June 16. Options traders moved defensively into that dip, but the overall structure still shows calls outnumbering puts by a wide margin. The ORTEX short score of 61.3 has eased slightly from its recent peak above 62, consistent with a stock where short pressure is elevated but not accelerating further.
Institutional ownership reflects a high-conviction biotech register. Paradigm Biocapital and Baker Bros. are the two largest holders at roughly 6.8% and 6.1% respectively. Janus Henderson added over 1.3 million shares in Q1. Braidwell cut nearly 2.9 million shares in the same period — the largest institutional reduction on record here — which may partly explain the short interest rebuilding as freed-up borrow found new users. The net insider picture over 90 days shows sales totalling around $4.2 million, driven entirely by CMO Joanne Donovan's programmatic sales in March through May. No purchases are recorded in the period.
The next hard catalyst is Q2 earnings on August 6, when the CIRRUS readout timeline and cash runway update will dominate. The last two earnings events both produced negative single-day moves in the 3-4% range, with five-day declines of 1-8%. The gap between the RBC bull case at $59 and Goldman's neutral-to-bearish perch at $32 means the August print, and the CIRRUS data ahead of it, will likely decide which side of that debate carries weight into year-end.
See the live data behind this article on ORTEX.
Open EWTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
